Orthofix (NSDQ:OFIX) has appointed Jon Serbousek — a 30-year veteran of the medical device and biotech industries — as its new president and CEO.
The Lewisville, Texas–based orthopedic device company announced the appointment on Nov. 1, saying it was effective immediately. Serbousek takes over for Brad Mason, who previously announced his plan to retire. Mason will continue as a consultant for 12 months to assist with the transition.
“We are grateful for Brad’s many contributions to Orthofix. Under his leadership a strong foundation was built that will serve Orthofix well in the years ahead,” Ron Matricaria, chair of Orthofix’s board of directors, said in a news release.
“I am confident in Jon’s ability to deliver against our strategic business priorities. His vast experience in the medical device industry and focus on business growth and value creation will be a benefit to our organization,” Matricaria said.
Serbousek’s career has included several leadership positions at Biomet (now Zimmer Biomet), including worldwide president of Biomet Biologics, worldwide group president of Orthopedics, and president of U.S. Orthopedics. Before Biomet, he held general management positions at Medtronic, including worldwide division president of Spine, and worldwide VP and GM of Biologics for Medtronic’s Spine and Biologics business. He also spent 13 years with DePuy Orthopedics.
